ArticleJournal of hepatocellular carcinoma2025
Identification of FDFT1 and PGRMC1 as New Biomarkers in Nonalcoholic Steatohepatitis (NASH)-Related Hepatocellular Carcinoma by Deep Learning.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The evolution of artificial intelligence technology in non-alcoholic fatty liver disease.Frontiers in radiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With the global epidemic of obesity and diabetes, non-alcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver disease, and NASH is increasingly becoming a major risk factor for hepatocellular carcinoma. Therefore, it is essential to explore novel biomarkers in NASH-related HCC. Methods: Deep Learning (DL) methods are a promising and encouraging tool widely used in genomics by automatically applying neural networks (NNs). Therefore, DL, "limma package", weighted gene co-expression network analysis (WGCNA), and Protein-Protein Interaction Networks (PPI) were used to screen feature genes. Real-time quantitative PCR was used to validate the expression of feature genes in the NAFLD mice model. Enrichment and single-cell sequencing analyses of single genes were performed to investigate the role of feature genes in NASH-related HCC. Results: Combined core genes screened by DL in NAFLD with important genes in metabolic syndrome, six feature genes (FDFT1, TNFSF10, DNAJC16, RDH11, PGRMC1, and MYC) were obtained. ROC analysis demonstrates the model's superiority with the AUC was 0.983 (0.9241-0.98885). Animal experiments based on NAFLD mouse models have also shown that FDFT1, TNFSF10, DNAJC16, RDH11, and PGRMC1 have a higher expression in NAFLD livers. Among the feature genes, FDFT1 and PGRMC1 showed significant expression trends and outstanding diagnosis value in NASH-HCC. Conclusion: In conclusion, FDFT1 and PGRMC1 are key enzymes in the cholesterol synthesis pathway, our study validates the important role of cholesterol metabolism in NAFLD from another perspective, implying they may be new prognostic and diagnostic markers for NASH-HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.